AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
By Elana Gotkine HealthDay Reporter
TUESDAY, Nov. 12, 2024 -- For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial infarction (MI), and recurrent stroke, according to a study presented at the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.
Mohammad Ali Sheffeh, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among adults with ischemic stroke. Data were included for 7,044 individuals (mean age, 72 ± 14 years).
The researchers found that 6 percent of the participants had a second stroke, 6 percent had an incident MI, and 53 percent died during a median follow-up of three years. In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite. After multivariable adjustment, these associations remained significant and were not affected by minimum time of exposure. In the multivariate analysis, SGLT-2i/GLP-1 RA use was also associated with recurrent ischemic stroke. In most sub-analyses of individual medications, all associations remained significant, except for the association between GLP-1 RA and recurrent stroke.
"The results of the study are consistent with other research about the preventive role of these medications against cardiovascular disease in people with obesity or heart failure," Sheffeh said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Pathological Fatigue Common Up to 12 Months After TIA
WEDNESDAY, May 14, 2025 -- Pathological fatigue is common up to 12 months after a diagnosis of transient ischemic attack (TIA), according to a study published online May 14 in...
No Benefit Seen for Revascularization Added to Drug Therapy in Carotid Stenosis
FRIDAY, May 2, 2025 -- For patients with asymptomatic or symptomatic carotid stenosis of 50 percent or greater with a low or intermediate predicted stroke risk, there is no...
Early Combination of Lipid-Lowering Therapy Beneficial After Myocardial Infarction
MONDAY, April 28, 2025 -- For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial, according to a study published online in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.